Business Context and Reporting Period
This Form 6-K filing by Celsus Therapeutics Plc (formerly Akari Therapeutics Plc) is dated June 20, 2013. The report details the outcomes of the Company's Annual General Meeting (AGM) held on June 30, 2013. The filing confirms the receipt of audited financial statements for the year ended December 31, 2012, prepared under both US GAAP and IFRS.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It only confirms that the financial statements for the year ended December 31, 2012, were presented and approved by shareholders.
Material Changes and Corporate Actions
- Corporate Name Change: The Company's registered name was officially changed to Celsus Therapeutics Plc.
- Governance Updates:
- Saul Yedgar was re-appointed as a Class A Director.
- Fredric Price and Robert (Bob) Doman were elected as new Class A Directors.
- Kost, Forer Gabbay & Kasierer (Ernst & Young Global) were re-appointed as auditors.
- Stock Option Plan: Shareholders approved the 2007 Stock Option Plan and its amendments. The aggregate number of shares issuable under the plan is capped at 3,865,000 shares, subject to adjustments.
- Articles of Association: Amendments were made to add a new regulation 10, along with consequential definitions and renumbering of existing regulations.
Guidance, Outlook, and Risks
The filing does not contain management commentary regarding future guidance, outlook, specific risks, contingencies, or unusual items. The document is strictly a report of corporate governance actions and shareholder resolutions.
Key Facts for Investor Verification
- Verify the full text of the audited financial statements for the year ended December 31, 2012, as specific metrics are not included in this summary filing.
- Confirm the impact of the name change to Celsus Therapeutics Plc on trading symbols and market data.
- Review the specific terms of the amended 2007 Stock Option Plan to understand dilution risks associated with the 3,865,000 share cap.
- Check the updated Articles of Association for the implications of the new Regulation 10.